Click image to view original image
Quick Detail:
|
Product name |
Norgestimate |
|
Other name |
Dexnorgestrel acetime, Norgestimato, Norgestimatum, Ortho-Prefest, Norgestimatum |
|
CAS register number |
35189-28-7 |
|
Molecular formula |
C23H31NO3 |
|
Molecular weight |
369.5 |
|
Appearance |
White or white crystalline powder |
|
Molecular structure |
|
|
Assay |
98% |
Description:
Norgestimate is a form of progestin, which is a female hormone important for the regulation of ovulation and menstruation. Norgestimate is used with estradiol (a female sex hormone that is involved in the development and maintenance of the female reproductive system), to treat the symptoms of menopause.
Norgestimate and ethinylestradiol are used as an oral contraceptive, indicated for the prevention of pregnancy in women.
Application:
Norgestimate/ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Formulations/Preparations
Norgestimate is available commercially as a component of a combination tablet with ethinylestradiol.
Drug warning:
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Oral contraceptives should not be used in women who currently have the following conditions: thrombophlebitis or thromboembolic disorders; a past history of deep vein thrombophlebitis or thromboembolic disorders; cerebral vascular or coronary artery disease (current or past history); valvular heart disease with complications; severe hypertension; diabetes with vascular involvement; headaches with focal neurological symptoms; major surgery with prolonged immobilization; known or suspected carcinoma of the breast or personal history of breast cancer; carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; acute or chronic hepatocellular disease with abnormal liver function; hepatic adenomas or carcinomas; known or suspected pregnancy; hypersensitivity to any component of this product.
The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity and diabetes.
